NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Saint Louis University's Center for Vaccine Development will enroll up to 30 healthy adult volunteers in a Phase 1 clinical trial to evaluate the safety and immune response of an updated investigational West Nile virus vaccine.

The U.S. Department of Health and Human Services and NIH have announced "Generation Gold Standard," a next-generation universal vaccine platform using beta-propiolactone-inactivated whole-virus technology.

INOVIO Pharmaceuticals reports promising Phase I results for its DMAbs technology, showing 100% of subjects maintained relevant antibody levels with no serious adverse events.

The National Institutes of Health has initiated the first human trial of Moderna's mRNA-1215 vaccine targeting Nipah virus, a deadly pathogen with a 40-70% fatality rate.

At the 2025 Conference on Retroviruses and Opportunistic Infections (CROI), researchers presented promising results from multiple HIV cure trials, suggesting potential for wider therapeutic applications.

The NIH has initiated a Phase 1 clinical trial of LASSARAB, a novel vaccine candidate for Lassa fever, a viral hemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of patients.

NIH/NIAID has launched a Phase 2 clinical trial of Corvus Pharmaceuticals' soquelitinib for autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease typically manifesting by age two.

Kenox Pharmaceuticals and Lactiga have formed a strategic collaboration to develop novel secretory IgA (sIgA) therapies for immunodeficient patients, supported by a multi-million-dollar NIAID grant.

The US is experiencing a significant H5N1 avian influenza outbreak affecting over 800 dairy herds across 16 states, with 66 confirmed human cases and one death reported in early 2025.

Xolair, initially approved for asthma in 2003, has now been FDA-approved for treating food allergies, offering relief to millions with severe allergic reactions.